Archives

Find out the full program here: http://www.biocapitaleurope.com

Basel, Switzerland – 6 November 2017 Nouscom, an oncology company developing neoantigen cancer vaccines based on its Exovax platform, today announced the completion of a €42 million Series B [...]

Full program: http://www.sachsforum.com/uploads/5/1/9/6/51964431/17thbef-finalagenda.pdf

Mainz, Germany Abstract Title: Great Apes Adenovirus neoantigens vaccine synergizes with immunomodulators in mouse models of cancer.

EMBL Heidelberg, Germany Full program: https://am.asco.org

Basel, Switzerland – May, 17 2016 Nouscom announced today that it has closed a EUR 12 million Series A financing co-led by LSP and Versant Ventures. The funds will be used to support discovery [...]

NousCom will present at the 17th Biotech In Europe Forum for Global Partnering and Investment. The forum wiil take place on 26th-27th September at the Congress Center Basel (switzerland). Feel [...]

EMBL Heidelberg, Germany Abstract Title: Personalized cancer vaccine based on ChAd vaccine improves over the anti-PD1 activity.

Palma, Mallorca Abstract Title: Development of cell based immunity based on multiple epitopes: Lessons from prophylactic genetic vaccines.

ABSTRACT BACKGROUND The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for [...]